Coherus Oncology (CHRS) Jefferies Global Healthcare Conference 2026 summary

Strategic focus and business model

• Transitioned to a pure immuno-oncology focus after divesting biosimilars, centering on LOQTORZI, tagmokitug, and casdozokitug.

• LOQTORZI serves as both a commercial backbone and a platform for combination therapies, with global rights and ex-U.S. licensing opportunities.

• Targeting a $33 billion product opportunity by combining novel agents with LOQTORZI for label expansion and global reach.

• Multiple supply agreements and plans for further global deals as data matures.

• Enhanced commercial infrastructure and data analytics to drive targeted sales and educational outreach.

LOQTORZI clinical and commercial progress

• LOQTORZI, a next-gen PD-1 inhibitor, shows strong differentiation and high affinity, with unique binding and clinical benefits in low PD-L1 cancers.

• Demonstrated significant survival benefit: patients on chemo plus LOQTORZI nearly double survival compared to chemo alone.

• Approved in the EU for low PD-L1 esophageal cancer and recognized as a preferred regimen for nasopharyngeal cancer.

• Commercial team expansion and targeted programs aim for $15M/quarter in 2024, $30–35M/quarter by 2027, and $175M annual run rate by 2028.

Tagmokitug (CCR8 Treg depleter) development

• Tagmokitug targets Treg depletion to enhance immune response across solid tumors, with broad applicability in combination with PD-1, radiation, and T-cell engagers.

• Recent J&J partnership marks first anti-CCR8 use with T-cell engager in prostate cancer, with data expected late 2024 or early 2025.

• Demonstrated best-in-class selectivity, strong immune activation, and no dose-limiting toxicities up to 1,200 mg.

• Clinical expansion includes head and neck, GI, and prostate cancers, with mid-2026 readout for head and neck and ongoing enrollment in GI studies.

• Strategy includes broad development and partnerships for use in radiation, ADCs, and T-cell engagers.